

Safe and efficient implementation of Dengvaxia – tackling remaining challenges
Tuesday 6th June, 2017, Wellcome Trust

Session 1: Dengvaxia – benefits, risks, and WHO’s recommendation for use (chair: S. Flasche)

9:00	S Flasche	Welcome
9:10	P Smith	Dengvaxia – benefits and risks – clinical evidence
9:40	M Recker	Dengvaxia – benefits and risks – modelling evidence
10:10	M Jit	Dengvaxia – cost effectiveness
10:30	K Vannice	WHO recommendations, decision making support for countries and status of other vaccines candidates
11:00	Coffee	

Session 2: Challenges for country level implementation (chair: A Scott)

11:30	LC Ng	Local challenges for Dengvaxia implementation and global consequences
12:00	H Tissera	Risks and benefits of Dengvaxia implementation
12:30	Lunch	

Session 3: Operationalising Dengvaxia and optimising its impact (chair: A Kucharski)

13:30	I Longini	Optimal serosurvey design to inform dengue vaccine introduction
14:00	D Cummings	Linking serology, surveillance and risk factors to predict fine scale dengue seroprevalence
14:30	L Coudeville	Assessing transmission intensity and the value of serotesting
15:00	H Larson	Vaccine confidence and communication strategies. Lessons learned from HPV
15:20	Coffee	

Session 4: Post licensure monitoring (chair: P Smith)

15:50	O Wichmann	Post-licensure study designs - what is needed and what is feasible?
16:10	Sanofi Pasteur	FYI: Ongoing and planned phase IV studies

Session 5: Panel discussion (moderator: M Jit)

16:30	All speakers	Interactive panel discussion on way forward with dengue vaccination (in particular post licensure studies)
17:30	Drinks reception	
18:30	Speakers dinner	